Esketamine’s Neurobehavioral Impact in Zebrafish: Preclinical Insights and Clinical Implications

Esketamine Alters Zebrafish Neurodevelopment and Behavior in Dose- and Exposure-Dependent Ways

A systematic review published in October 2026 (OpenAlex W7221842390) synthesizes preclinical evidence that esketamine, an NMDA receptor antagonist, produces significant neurobehavioral changes in zebrafish (Danio rerio) depending on dose and timing of exposure. The review analyzed five studies (all from China, 2024–2026) that used zebrafish models to assess behavioral and neurodevelopmental outcomes following esketamine administration. Acute larval exposure led to hyperactivity, while embryonic or prolonged exposure resulted in hypoactivity, neurotoxicity, and impaired development.

This biphasic effect—acute disinhibition versus chronic suppression—mirrors the dual nature of esketamine’s pharmacology and underscores the importance of exposure timing and dosing in translational research.

Mechanisms: NMDA Receptor Inhibition, Oxidative Stress, and Transcriptomic Changes

Esketamine’s primary mechanism in both clinical and preclinical models is antagonism of the N-methyl-D-aspartate receptor (NMDAR), a key modulator of glutamatergic neurotransmission. In zebrafish, acute exposure to esketamine inhibited NMDAR function, leading to increased locomotor activity—a proxy for the drug’s rapid antidepressant effects observed in mammals. However, repeated or developmental exposure induced transcriptomic changes, oxidative stress, neuronal apoptosis, and ultimately hypoactivity.

Notably, the review found that environmental concentrations of esketamine—reflecting potential pharmaceutical contamination—produced only subtle anesthetic effects, suggesting a threshold below which neurotoxicity may not manifest. This finding is rarely discussed in clinical literature but may inform environmental and occupational safety standards as esketamine use expands.

Policy and Research Implications: Caution Urged for Repeated or High-Dose Use

The zebrafish data highlight potential neurodevelopmental and neuropsychiatric risks associated with repeated or high-dose esketamine exposure, especially during critical periods of brain development. While the acute antidepressant effects of esketamine are well-documented in humans, these preclinical findings suggest that chronic or off-label use, particularly in vulnerable populations such as adolescents or pregnant individuals, warrants careful risk assessment.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) may need to revisit post-marketing surveillance protocols and consider requiring long-term neuropsychiatric outcome studies, especially as esketamine is increasingly prescribed for treatment-resistant depression and explored for other indications. The review also underscores the value of zebrafish as a high-throughput, genetically tractable model for early neurotoxicity screening—a point not yet fully leveraged in current regulatory frameworks.

Risks, Unknowns, and Translation Challenges

While zebrafish offer unique advantages for neurodevelopmental studies, several caveats limit direct extrapolation to humans. Differences in brain complexity, metabolism, and developmental timelines mean that observed neurotoxic effects may not fully predict human outcomes. Nevertheless, the dose- and exposure-dependent risks identified—especially transcriptomic disruption and neuronal apoptosis—raise important questions about the long-term safety of repeated esketamine administration in clinical settings.

One real-world failure mode not widely discussed is the possibility of cumulative neurotoxicity in patients receiving frequent or high-dose esketamine infusions for chronic psychiatric indications. Current clinical trials (e.g., NCT02493868) typically focus on short-term efficacy and acute adverse events, with limited follow-up on neurodevelopmental or cognitive endpoints. This systematic review highlights the need for longitudinal human studies that specifically assess neurocognitive and neurodevelopmental trajectories post-treatment.

Looking Forward: Integrating Preclinical Signals into Clinical Practice and Policy

The 2026 systematic review of esketamine’s neurobehavioral effects in zebrafish adds a nuanced layer to the ongoing debate over the drug’s risk-benefit profile. As esketamine’s clinical use expands, integrating preclinical toxicity signals—especially those related to developmental exposure—into trial design, patient selection, and regulatory oversight will be essential. Future research should prioritize cross-species validation of neurotoxicity markers, long-term outcome tracking, and the development of safer dosing regimens.

For clinicians and policymakers, the key insight is that the therapeutic window for esketamine may be narrower than previously assumed, particularly for repeated or off-label use. Ongoing vigilance, transparent reporting, and adaptive regulation will be critical as the field navigates the balance between rapid antidepressant effects and potential long-term neuropsychiatric risks.

Byline: Dr. Alexei M. Torres, PhD (Neuropharmacology). How we research: This article was reviewed by Dr. Torres on 2026-10-15, drawing on the original systematic review (OpenAlex W7221842390), clinical trial registries, and regulatory agency guidance.